11 March 2009 in Journal of Medical Genetics
T(The Jichi Community Genetics Team (JCOG)
The Jichi Community Genetics Team (JCOG)
+6
Background: Recent genome wide association studies discovered seven novel loci that influence plasma concentrations of triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol in Europeans. To date, large scale replication studies using populations with known differences in genome-wide linkage disequilibrium (LD) pattern have not been undertaken. Methods: To address this issue, we tested associations between single nucleotide polymorphisms (SNPs) within the seven novel loci and plasma lipid profiles in 21 010 Japanese individuals. Results: Multiple linear regression analyses showed that the rs3812316 in MLXIPL was strongly associated with triglyceride concentrations (p∼3.0×10−11, 7.1 mg/dl decrease per minor C allele) and that rs599839 in CELSR2/PSRC1/SORT1 was strongly associated with LDL cholesterol concentrations (p∼3.1×10−11, 4.7 mg/dl decrease per minor G allele) in the Japanese population. SNPs near ANGPTL3, TRIB1 and GALNT2 showed evidence for associations with triglyceride concentrations (3.6×10−6<p<5.1×10−5). SNP near TRIB1 showed association with LDL cholesterol concentrations (p∼1.2×10−5). On the other hand, SNPs in NCAN/CILP2/PBX4 and MVK/MMAB were not associated with any plasma lipid profiles in the Japanese population. Ethnic differences in LD pattern would explain the lack of association between these two loci and plasma lipid concentrations in the Japanese population. Conclusion: Associations between the novel loci and plasma lipid concentrations were generally conserved in the Japanese population, with the exception of NCAN/CILP2/PBX4 and MVK/MMAB.
3 April 2010 in Human Genetics
JJJichi Medical University Promotion Team of a Large-scale Human Genome Bank for All over Japan
Jichi Medical University Promotion Team of a Large-scale Human Genome Bank for All over Japan
+7
1 August 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Objective—: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate-limiting step in cholesterol biosynthesis and has proven to be an effective target of lipid-lowering drugs, statins. The aim of this study was to understand the role of hepatic HMGCR in vivo. Methods and Results—: To disrupt the HMGCR gene in liver, we generated mice homozygous for a floxed HMGCR allele and heterozygous for a transgene encoding Cre recombinase under the control of the albumin promoter (liver-specific HMGCR knockout mice). Ninety-six percent of male and 71% of female mice died by 6 weeks of age, probably as a result of liver failure or hypoglycemia. At 5 weeks of age, liver-specific HMGCR knockout mice showed severe hepatic steatosis with apoptotic cells, hypercholesterolemia, and hypoglycemia. The hepatic steatosis and death were completely reversed by providing the animals with mevalonate, indicating its essential role in normal liver function. There was a modest decrease in hepatic cholesterol synthesis in liver-specific HMGCR knockout mice. Instead, they showed a robust increase in the fatty acid synthesis, independent of sterol regulatory element binding protein-1c. Conclusion—: Hepatocyte HMGCR is essential for the survival of mice, and its abrogation elicits hepatic steatosis with jaundice and hypoglycemia.
1 July 2010 in Diabetes Research and Clinical Practice
1 January 2011 in Journal of Atherosclerosis and Thrombosis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
1 November 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Objective—: Inhibition of HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is atheroprotective primarily by decreasing plasma LDL (low-density lipoprotein)-cholesterol. However, it is unknown whether inhibition of HMGCR in myeloid cells contributes to this atheroprotection. We sought to determine the role of myeloid HMGCR in the development of atherosclerosis. Approach and Results—: We generated mice with genetically reduced Hmgcr in myeloid cells ( Hmgcr
m−
/m
− ) using LysM (Cre) and compared various functions of their macrophages to those of Hmgcr
fl/fl
control mice. We further compared the extent of atherosclerosis in Hmgcr
m
−/
m
−
and Hmgcr
fl/fl
mice in the absence of Ldlr (LDL receptor). Hmgcr
m
−/
m
−
macrophages and granulocytes had significantly lower Hmgcr mRNA expression and cholesterol biosynthesis than Hmgcr
fl/fl
cells. In vitro, Hmgcr
m
−/
m
−
monocytes/macrophages had reduced ability to migrate, proliferate, and survive compared with Hmgcr
fl/fl
monocytes/macrophages. However, there was no difference in ability to adhere, phagocytose, store lipids, or polarize to M1 macrophages between the 2 types of macrophages. The amounts of plasma membrane–associated small GTPase proteins, such as RhoA (RAS homolog family member A), were increased in Hmgcr
m
−/
m
−
macrophages. In the setting of Ldlr deficiency, Hmgcr
m
−/
m
−
mice developed significantly smaller atherosclerotic lesions than Hmgcr
fl/fl
mice. However, there were no differences between the 2 types of mice either in plasma lipoprotein profiles or in the numbers of proliferating or apoptotic cells in the lesions in vivo. The in vivo migration of Hmgcr
m
−/
m
−
macrophages to the lesions was reduced compared with Hmgcr
fl/fl
macrophages. Conclusions—: Genetic reduction of HMGCR in myeloid cells may exert atheroprotective effects primarily by decreasing the migratory activity of monocytes/macrophages to the lesions.